about
Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritisMicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritisPTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis.Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritisMicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritisCollagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid ArthritisTapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis.ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature.Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations.Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients.Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment.Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons.ZAP-70+ B cell subset influences response to B cell depletion therapy and early repopulation in rheumatoid arthritis.Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone.Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression.Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsAEvaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trialsBiomarkers of Joint Damage in Rheumatoid Arthritis: Where Are We in 2013?Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung diseaseSkin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healingDifferential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis.Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of ImmunogenicityJAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapyOverweight/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid ArthritisComment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel diseaseMeasuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkersAmplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic diseaseReal-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD studyTelemedicine will not keep us apart in COVID-19 pandemic
P50
Q28218493-EDA57175-E740-4A16-9AAF-F5E3426DFFE5Q33849824-DE8A6277-3A55-474E-9153-9897FA13AEC1Q34031304-9075761D-7E9B-4F38-A52C-53965BC8F535Q34274249-C34AC835-18EB-4008-B70A-221529EF03C5Q35091092-553840D4-8B24-4A01-87FD-858F446642B5Q36437722-9E6BCC64-9874-4EB9-BA76-B842223D7806Q36543127-78C21DA5-C424-4BB5-8817-8BDF5F312F9CQ37315021-BE4287E2-A218-4F5D-B91A-EC0B7B456934Q37626889-8D297231-6110-46FB-ADC7-B5A7C720865FQ38763702-B610BECE-C08F-42ED-B601-AB5E0C0C223FQ39748097-36FE9827-613F-4726-9817-97B332420E7CQ41146155-87BD869D-89CA-4FAF-BA24-B4504C5DE4DCQ45954946-5B7C76A6-E539-4107-BFFB-EC07B07B473DQ50128295-5E4F4521-A690-431A-9436-8EF40DCBEE63Q50937787-C2305349-49D8-455D-91EE-90D06C8A1FFBQ52879316-9034A5AD-FE94-43BA-A8E3-A447C26C952BQ55261205-F8B40E3E-B0F8-49AD-9A63-04D5047E25E3Q57112378-696748B0-3EB7-4CFD-85F1-6AF2DA1AD3A8Q57231953-DE057EBF-7D9B-493D-9B38-C4F497A57261Q57753150-C878E3C7-1AEA-4B8B-A3DD-BEC3E1A404AEQ57753247-0E12E91D-7671-4325-B3B4-85ABC1D9C759Q57753603-F3EDD9CD-85B9-4E48-86A3-991850E01B74Q64929180-36E5151C-D4BC-4CB1-BFB1-40B4DAC3DD93Q90936305-78998D30-2622-4395-8850-309737902A3CQ91948622-BB7B20AC-3393-4274-B2FA-CBD4C24081DFQ92003457-E58C202E-6E2B-4C64-AFB5-BBA2D851FD30Q92213106-B11D6F18-A6A7-46E2-9EFE-EA0B74C0EB7AQ92538770-98966D70-B50C-44A7-87F9-28B756D2F46EQ92931340-8A373DCB-3355-435A-9BF9-A5178C7202C5Q93136347-302626C8-0861-463E-9153-366CD8ED60DCQ96171109-46610702-996C-4A80-8B55-9DD79128FC47
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stefano Alivernini
@ast
Stefano Alivernini
@en
Stefano Alivernini
@es
Stefano Alivernini
@nl
type
label
Stefano Alivernini
@ast
Stefano Alivernini
@en
Stefano Alivernini
@es
Stefano Alivernini
@nl
prefLabel
Stefano Alivernini
@ast
Stefano Alivernini
@en
Stefano Alivernini
@es
Stefano Alivernini
@nl
P106
P1153
25631952600
P21
P31
P496
0000-0002-7383-4212